$PRTK Not much downside here imo. Q4 Nuzyra revs should be 5-6mm, annualize it to 25mm next year. Selling the drug at 4x peak revenue would give us 100mm, which is more than the current market cap. Only problem with this estimation: It assumes stagnating revenues. Realistically, we should expect solid growth and peak revenues much higher than 25mm. Guidance in Q4 ER could send this up significantly already.
  • 4
  • 2